Relay Therapeutics (RLAY) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChart

Relay Therapeutics Revenue Highlights


Latest Revenue (Y)

$25.55M

0

Relay Therapeutics Revenue by Period


Relay Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$25.55M1749.82%
2022-12-31$1.38M-54.41%
2021-12-31$3.03M-96.34%
2020-12-31$82.65M100.00%
2019-12-31-100.00%
2018-12-31--

Relay Therapeutics generated $25.55M in revenue during NA 2023, up 1749.82% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Relay Therapeutics Revenue by Quarter

DateRevenueChange
2024-06-30--100.00%
2024-03-31$10.01M-1000800.00%
2023-12-31$-1.00K-100.00%
2023-09-30$25.20M21078.15%
2023-06-30$119.00K-47.35%
2023-03-31$226.00K-10.67%
2022-12-31$253.00K-26.45%
2022-09-30$344.00K-5.75%
2022-06-30$365.00K-12.89%
2022-03-31$419.00K-26.10%
2021-12-31$567.00K-14.86%
2021-09-30$666.00K-21.09%
2021-06-30$844.00K-11.34%
2021-03-31$952.00K-98.85%
2020-12-31$82.65M100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31--

Relay Therapeutics generated - in revenue during Q2 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Relay Therapeutics Revenue Breakdown


Relay Therapeutics Revenue Breakdown by Product

Quarterly Revenue by Product

Product/ServiceSep 22Jun 22Mar 22
License$300.00K$300.00K$200.00K

Relay Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 22: License (100.00%).

Relay Therapeutics Revenue Breakdown by Country

Quarterly Revenue by Country

CountrySep 22Jun 22Mar 22
License$300.00K$300.00K$200.00K

Relay Therapeutics's latest quarterly revenue breakdown by geography, as of Sep 22: License (100.00%).

Relay Therapeutics Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
AMLXAmylyx Pharmaceuticals$380.79M$88.64M
APLSApellis Pharmaceuticals$366.28M$179.14M
BPMCBlueprint Medicines$249.38M$138.16M
ARVNArvinas$78.50M$76.50M
NRIXNurix Therapeutics$76.99M$12.09M
FHTXFoghorn Therapeutics$34.16M$6.89M
RLAYRelay Therapeutics$25.55M-
STOKStoke Therapeutics$8.78M$4.22M
IPSCCentury Therapeutics$2.23M$771.00K
PLRXPliant Therapeutics$1.58M-
LIFEaTyr Pharma$353.00K$235.00K
CGEMCullinan Oncology--
BDTXBlack Diamond Therapeutics--
CCCCC4 Therapeutics--
DAWNDay One Biopharmaceuticals-$8.19M
TERNTerns Pharmaceuticals--
MLYSMineralys Therapeutics--
GLUEMonte Rosa Therapeutics-$4.70M
EWTXEdgewise Therapeutics--

RLAY Revenue FAQ


Relay Therapeutics's yearly revenue for 2023 was $25.55M, representing an increase of 1749.82% compared to 2022. The company's yearly revenue for 2022 was $1.38M, representing a decrease of -54.41% compared to 2021. RLAY's yearly revenue for 2021 was $3.03M, representing a decrease of -96.34% compared to 2020.

Relay Therapeutics's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $10.01M, a -1000800.00% decrease from the previous quarter (Q4 2023), and a 4327.88% increase year-over-year (Q1 2023). RLAY's quarterly revenue for Q4 2023 was $-1K, a -100.00% decrease from the previous quarter (Q3 2023), and a -100.40% decrease year-over-year (Q4 2022).

Relay Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 743.38%, and for the last 5 years (2019-2023) was 0%.